Sirnaomics Ltd. (HK:2257) has released an update.
Sirnaomics Ltd. has announced the successful completion of IND-enabling studies for STP125G, a potential new treatment for cardiovascular diseases targeting ApoC3, with positive safety and efficacy results from non-human primate models. The findings are expected to pave the way for a Phase I clinical trial submission to the U.S. FDA. However, the company cautions shareholders and potential investors that the success of STP125G’s market release is not guaranteed.
For further insights into HK:2257 stock, check out TipRanks’ Stock Analysis page.
